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Abstract We studied a Malian family with parental consan-
guinity and two of eight siblings affected with late-childhood-
onset progressive myoclonus epilepsy and cognitive decline,
consistent with the diagnosis of Lafora disease. Genetic
analysis showed a novel homozygous single-nucleotide
variant in the NHLRC1 gene, c.560A>C, producing the
missense change H187P. The changed amino acid is highly
conserved, and the mutation impairs malin's ability to degrade
laforin in vitro. Pathological evaluation showed manifesta-
tions of Lafora disease in the entire brain, with particularly
severe involvement of the pallidum, thalamus, and cerebel-
lum. Our findings document Lafora disease with severe
manifestations in the West African population.
Keywords Clinicalneurology.Epilepsy/seizures.
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Introduction
Lafora disease (LD) was first described in 1911 as a fatal
form of progressive myoclonus epilepsy with onset in the
late first or second decade of life [1]. LD is an autosomal
recessive disease and causes progressive tonic-clonic seiz-
ures, myoclonic jerks, loss of motor control, and intellectual
decline. The diagnosis is based on clinical findings, the
presence of intracellular polyglucosan inclusions (Lafora
bodies, LBs) in neurons and other cell types, including liver
and skin [2, 3], and genetic analysis. At least three genes are
associated with LD, of which two have been identified:
EPM2A and NHLRC1 (NHL repeat containing 1, EPM2B)
[4]. The EPM2A gene product, laforin, is a carbohydrate
phosphatase, and NHLRC1 encodes the protein malin, an E3
ligase that ubiquitinates and promotes the degradation of
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[5–8]. Mutations in laforin and malin lead to the production
of LBs, which are deposits of starch-like polyglucosans,
insufficiently branched and, hence, insoluble glycogen
molecules [9]. The mechanism of neurotoxicity has not been
elucidated, but the activity of complexed malin–laforin in the
degradation of misfolded protein could explain why reces-
sive mutations in either gene lead to Lafora disease [10].
Lafora disease is a rare disease encountered worldwide,
including Eastern and Northern Africa [11–17]. However, to
our knowledge, no case has been reported in West Africa. In
this paper, we report a Malian family affected by Lafora
disease with a novel mutation in the NHLRC1 gene.
Materials and methods
All adult subjects and parents of minors gave written
consent before participation in the research protocol used
for this study. The protocol was reviewed and approved by
the NINDS Institutional Review Board and the Ethical
Committee at the University of Bamako. All subjects
provided a detailed medical and family history and
underwent neurological evaluation and genetic counseling.
Computed tomography (CT) brain scan, electroencephalo-
gram (EEG), blood chemistries, and genetic testing were
performed. DNA was extracted from peripheral blood with
the Qiagen PAXgene Blood DNA kit (Qiagen, Valencia,
CA USA) and was sent to Athena Diagnostics, Inc.,
Worcester, MA, USA, for genetic analysis. Direct sequenc-
ing of the EPM2A and NHLRC1 genes was done with
polymerase chain reaction-amplified genomic DNA
obtained from one sib. Pathological studies were done with
brain tissue obtained postmortem from the other sib. The
tissue was received in formalin in excellent fixed condition.
After external examination, the brain was serially sectioned
in the coronal plane for gross examination and extensively
sampled for histopathologic evaluation. Tissues were
embedded in paraffin and all sections were stained initially
with hematoxylin and eosin. Selected sections were then
stained with luxol fast blue/periodic acid Schiff (LFB/PAS),
and immunohistochemical stains for CD68 and leucocyte
common antigen.
The effect of the mutation on malin and laforin
expression levels was investigated. Malin and laforin
DNA constructs were the kind gift of Matthew Gentry
and Jack Dixon. The malin H187P mutant was made using
the QuikChange XL site-directed mutagenesis kit (Strata-
gene) and confirmed by sequencing. Cos7 cells in a six-
well dish were transfected with 5 µg of FLAG-laforin or
empty pcDNA3.1 and 5 µg wild-type Malin-Myc, mutant
Malin-Myc, or empty pcDNA3.1 using 10 µL of Lipofect-
amine 2000 (Invitrogen). Cells were then collected by
centrifugation and lysed on ice in 1% NP-40 lysis buffer
supplemented with protease inhibitor cocktail (Roche) and
10 µM MG132 (Sigma). Total protein concentration was
quantitated using the Bio-Rad protein assay (Bio-Rad).
Twenty micrograms total protein was resolved on 10%
Tris–glycine gel (Novex, Invitrogen) and transferred to an
Invitrolon polyvinylidene fluoride membrane (Invitrogen)
for Western blot analysis. Membranes were blocked with
5% skim milk in Tris-buffered saline Tween-20 (TBST) and
incubated with primary antibody overnight at 4°C. To
detect levels of laforin, the monoclonal ANTI-FLAG M2
antibody (Sigma) was used, while malin was detected using
Myc-Tag Mouse mAb (Cell Signaling); both were diluted
1,000-fold in blocking solution. After three washes in
TBST, membranes were incubated for 2 h with peroxidase-
conjugated AffiniPure goat anti-mouse IgG (Jackson
ImmunoResearch) diluted 5,000-fold in blocking solution.
Results
Patients
Nineteen- and 16-year-old brothers with consanguineous
parents (Fig. 1) were evaluated for seizures and difficulty
walking.
Their medical history showed no problems at birth, and
psychomotor development was normal until the beginning
of adolescence. At ages 12 and 9, respectively, they
developed generalized tonic clonic seizures with visual
auras and aggressive behavior, for which they saw a
psychiatrist. The seizures occurred about once a month
initially and up to three to eight times per day over the last
2 years. They developed progressive difficulty with
walking and use of the hands. Later, they had reduced
verbal responsiveness, memory decline, and difficulty with
feeding and dressing. Memory and attention became
severely affected 4 to 5 years after symptom onset, and
they were no longer able to attend school. They developed
myoclonic jerks in the extremities, atonic seizures, increas-
ing clumsiness, and falls. The clinical exam showed
psychomotor retardation, dull expression, and little to no
vocalization. Occasional myoclonic jerks, worse with
action and sudden noise, were noted in the face, head,
trunk, and extremities. One patient required much assis-
tance in rising to a stand and was grossly ataxic, and the
other was bedridden during the examination. Reflexes were
normal to reduced, and there was increased tone in the legs.
Laboratory evaluations, including blood counts, sedimen-
tation rate, and serum chemistries such as liver enzymes
and electrolytes, were normal. An EEG showed generalized
spikes, polyspikes, and slow waves. A CT brain scan was
normal. Ophthalmologic examination was normal.
320 Neurogenetics (2009) 10:319–323The seizures were initially controlled with valproic acid,
and later, when they recurred, clonazepam was added.
Despite this treatment, both patients continued to have
seizures, and by 6 months after the initial exam, both were
bedridden. They were admitted to the hospital multiple
times for status epilepticus and respiratory infections. They
died at ages 20 and 16, respectively (8 and 7 years after
onset), with respiratory failure despite intensive care.
Family members reported that a cousin, also from a
consanguineous marriage, died from the same symptoms at
age 17. The clinical features and pattern of inheritance in
the family, as well as the EEG findings and the resistance to
anticonvulsant treatment, all suggested the diagnosis of
hereditary progressive myoclonus epilepsy.
Genetic analysis
Genetic analysis showed that the older sibling was
homozygous for a novel sequence variant (c.560A>C) in
the NHLRC1 gene. This nucleotide change is predicted to
result in a non-conservative amino acid substitution at
codon 187 (H187P). Analysis of this amino acid substitu-
tion with the BLOSUM similarity matrix gave a score of
−2, suggesting that the sequence variant alters the protein
structure and thus likely represents a deleterious mutation
[18]. In addition, this amino acid is highly conserved across
a broad range of different species, including mammals, fruit
fly, plants, and bacteria (Suppl. Fig. 1).
Functional analysis
In order to detect functional changes in malin with the
H187P mutation, we examined its ability to reduce steady-
state levels of laforin. Recombinant tagged laforin was
overexpressed in Cos7 fibroblast cells with tagged variants
of malin or empty vector. The steady-state levels of laforin
were observed 24 h after transfection. Compared with
empty vector, wild-type malin led to a marked reduction in
steady-state levels of laforin. Equivalent amounts of malin
with the H187P mutation failed to reduce levels of laforin
as effectively as wild-type malin. Malin with two other
disease-causing mutations (C26S and E280K) also failed to
reduce levels of laforin as efficiently as wild-type protein.
This demonstrates that the H187P mutation, which lies in
the second NHL domain, impairs malin's degradation of
laforin in vitro.
Brain pathology
Histologically, the brain tissue revealed scattered areas of
diffuse neuronal loss, mild gliosis, and variably sized PAS-
positive inclusions involving the entire cortex, basal
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Fig. 1 Pedigree of the family.
Note the consanguinity in both
families with at least one
affected individual in each
FLAG-Laforin
Malin-Myc
anti-FLAG Laforin
+         +        +         +         +         -
+          -      C26S H187P E280K  +
anti-Myc Malin
α-tubulin
Fig. 2 Mutant malin fails to reduce the steady-state levels of laforin
as efficiently as wild-type malin in Cos7 cells transfected with
recombinant tagged proteins
Neurogenetics (2009) 10:319–323 321ganglia, brainstem, and cerebellum to varying degrees, both
within neuronal perikarya and free in the neuropil (Suppl.
Fig. 2). The numerous intraperikaryonal inclusions showed
targetoid architecture with a basophilic core, frequently
associated with a surrounding amphophilic zone and/or
radial striae, consistent with Lafora bodies. The most
severely affected areas were the pallidum and thalamus,
followed by the cerebellum. The affected areas showed a
prominent diffuse microglial activation (confirmed by
immunohistochemistry for CD68 antigen); lymphoid infil-
tration was absent (confirmed by immunohistochemistry for
leucocyte common antigen).
Discussion
LD has been well described in the Mediterranean basin, the
Middle East and Asian countries, and North America, and
mutations in NHLRC1 are generally more common than in
EPM2A [11–14, 19, 20]. Patients have been reported in Africa
[15–17]; however, the diagnosis was based on skin biopsy,
which may have false positive results [21, 22]. Genetic
analysis was recently reported in two African families and
showed a mutation in the NHLRC1 gene in one (individual
F5) but no definitive mutation in the other (individual F6)
[23]. To our knowledge, there has been no clinically and
genetically confirmed LD reported in West Africa. Limited
access to medical evaluation and genetic testing may explain
the lack of reports of the disease in this region.
Studies have shown that patients with mutation in the
NHLRC1 gene in general have milder disease course and
later age of death compared to those with mutation in the
EPM2A gene [11, 19, 21, 24]. The ages of onset and
cognitive decline in the family reported here did not differ
from previous reports. However, the clinical course was
considerably more progressive than in most previously
reported patients with NHLRC1 mutations who generally
lose independence in activities of daily living at about 26 to
32 years of age and develop respiratory difficulties about
20 years after symptom onset [24]. Some patients with
EPM2B manifested symptoms at age 25 and completed
higher education [17, 23]; others had rare generalized tonic-
clonic seizures (one to four/year), moderate cognitive
impairment, and overall preservation of their activities of
daily living after reaching the third decade [25].
There is notreatmentforLD other thananticonvulsants and
respiratory assistance. The patients in the family reported here
were given valproic acid and clonazepam, and they had better
follow-up than the general population in Mali. Nonetheless,
this does not exclude the possibility that a lower level of
medical care contributed to the severity of the disease course.
A larger comparison study of other families with NHLRC1 in
the region might be informative in this regard.
The H187P mutation we found is in the second NHL
domain of the NHLRC1 product malin. Of the 51 NHLRC1
published mutations seen at least 156 times in unrelated
families [21, 26, 27], three are located in the second NHL
domain. Clinical details are not available; however, one
patient was reported to have symptoms at age 25 (G194C)
[23] and another presented with loss of cognitive function
at age 12 [11]. The ages of respiratory compromise and
death were not mentioned. No clinical information was
available for the third patient (D195N) [24].
Others have shown that pathogenic mutations, and in
particular mutations in the NHL domains, impair the
association of malin and laforin. While the mode of
toxicity is not well defined, it is clear that malin's
association with laforin is critical for the health of neurons.
One measure of this association is malin's ability to degrade
laforin. We have demonstrated that malin with the H187P
mutation is unable to promote the degradation of laforin as
well as the wild-type protein; this deficiency resembles the
functional change observed in two previously reported
mutations.
Our neuropathologic findings are generally consistent with
other LD patients, including another recently reported case
with NHLRC1 mutation [28]. Comparative neuropathologic
studies of patients with different EPM2A and NHLRC1
mutations in association with clinical assessment may help
to determine to what extent the phenotype correlates with
structural neuropathology. To this end, identification of novel
mutations with unusual clinical manifestations can help in
further characterizing the mechanism of the disease.
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